for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

84.68USD

Change

0.88(+1.05%)

Volume

3,162,184

Today's Range

83.67

 - 

84.90

52 Week Range

66.10

 - 

87.35

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

WHO Welcomes EMA's Recommendation Of Conditional Marketing Authorization For Merck's V920 Ebola Zaire Vaccine

Oct 18 (Reuters) - Merck & Co Inc <MRK.N>::WORLD HEALTH ORGANIZATION SAYS "WELCOMES" THE EMA ANNOUNCEMENT RECOMMENDING A CONDITIONAL MARKETING AUTHORIZATION FOR MERCK'S V920 EBOLA ZAIRE VACCINE.WORLD HEALTH ORGANIZATION SAYS WILL MOVE TOWARDS PREQUALIFICATION OF MERCK'S V920 EBOLA ZAIRE VACCINE.

Merck Receives Positive EU CHMP Opinion For Two New Regimens Of Keytruda (Pembrolizumab) As First-Line Treatment For Metastatic Or Unresectable Recurrent Head And Neck Squamous Cell Carcinoma

Oct 18 (Reuters) - Merck & Co Inc <MRK.N>::MERCK RECEIVES POSITIVE EU CHMP OPINION FOR TWO NEW REGIMENS OF KEYTRUDA® (PEMBROLIZUMAB) AS FIRST-LINE TREATMENT FOR METASTATIC OR UNRESECTABLE RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA.MERCK & CO - CHMP'S RECOMMENDATION WILL BE REVIEWED BY EUROPEAN COMMISSION FOR MARKETING AUTHORIZATION IN EU; FINAL DECISION IS EXPECTED IN Q4 2019.MERCK & CO INC - POSITIVE EU CHMP RECOMMENDATION IS BASED ON DATA FROM PIVOTAL PHASE 3 KEYNOTE-048 TRIAL.

Merck Receives EU CHMP Positive Opinion For Investigational V920 Ebola Zaire Vaccine For Protection Against Ebola Virus Disease

Oct 18 (Reuters) - Merck & Co Inc <MRK.N>::MERCK RECEIVES EU CHMP POSITIVE OPINION FOR INVESTIGATIONAL V920 EBOLA ZAIRE VACCINE FOR PROTECTION AGAINST EBOLA VIRUS DISEASE.MERCK & CO INC - ERVEBO IS CURRENTLY UNDER REVIEW IN UNITED STATES.MERCK - IF AFFIRMED BY EC, VACCINE TO BE INDICATED FOR ACTIVE IMMUNIZATION OF INDIVIDUALS 18 YEARS OF AGE OR OLDER.MERCK & CO INC - IF AFFIRMED BY EUROPEAN COMMISSION, V920 EBOLA ZAIRE VACCINE WILL BE AUTHORIZED UNDER BRAND NAME ERVEBO.MERCK & CO - CHMP OF EMA HAS ADOPTED POSITIVE OPINION RECOMMENDING CONDITIONAL MARKETING AUTHORIZATION FOR V920 EBOLA ZAIRE VACCINE.

4D Pharma Collaborates With MSD To Develop Live Biotherapeutics For Vaccines

Oct 8 (Reuters) - 4D Pharma PLC <DDDD.L>::4D PHARMA COLLABORATES WITH MSD TO DEVELOP LIVE BIOTHERAPEUTICS FOR VACCINES.ENTERED INTO RESEARCH COLLABORATION & OPTION TO LICENSE AGREEMENT WITH MSD, TRADENAME OF MERCK & CO., INC., KENILWORTH, NJ, USA.HAS RIGHT, SUBJECT TO CERTAIN CONDITIONS, TO CAUSE MSD TO PURCHASE $5 MILLION IN ORDINARY SHARES IN 4D DURING FIRST 12 MONTHS OF COLLABORATION.BESIDES UPFRONT CASH PAYMENT, 4D WILL BE ELIGIBLE TO RECEIVE UP TO $347.5 MILLION IN OPTION EXERCISE & DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS.MSD WILL BE RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING, COMMERCIALISATION FOLLOWING EXERCISE OF ANY OF ITS EXCLUSIVE OPTIONS.

Merck’s Keytruda Now Approved As Monotherapy In China

Oct 2 (Reuters) - Merck & Co Inc <MRK.N>::MERCK’S KEYTRUDA® (PEMBROLIZUMAB) NOW APPROVED AS MONOTHERAPY IN CHINA FOR FIRST-LINE TREATMENT OF CERTAIN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS EXPRESS PD-L1.MERCK & CO - NEW INDICATION WAS GRANTED FULL APPROVAL BASED ON OS FINDINGS FROM PHASE 3 KEYNOTE-042 TRIAL.

FDA Accepts 2 Applications For Merck's DIFICID (Fidaxomicin) To Treat Children Aged 6 Months To 18 Years With Clostridium Difficile Infections

Oct 2 (Reuters) - Merck & Co Inc <MRK.N>::FDA ACCEPTS TWO APPLICATIONS FOR MERCK’S DIFICID® (FIDAXOMICIN) TO TREAT CHILDREN AGED SIX MONTHS UP TO 18 YEARS WITH CLOSTRIDIUM DIFFICILE INFECTIONS.FDA ACCEPTS TWO APPLICATIONS FOR MERCK’S DIFICID® (FIDAXOMICIN) TO TREAT CHILDREN AGED SIX MONTHS UP TO 18 YEARS WITH CLOSTRIDIUM DIFFICILE INFECTIONS.MERCK & CO INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA), OR TARGET ACTION DATE FOR BOTH APPLICATIONS, IS SET FOR JAN. 24, 2020.

Merck says pivotal Phase 3 RECARBRI RESTORE-IMI 2 trial met primary endpoint

Sept 30 (Reuters) - Merck & Co Inc <MRK.N>::PIVOTAL RESTORE-IMI 2 PHASE 3 STUDY OF MERCK’S RECARBRIO™ (IMIPENEM, CILASTATIN, AND RELEBACTAM) IN HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) MET PRIMARY ENDPOINT.MERCK & CO INC - TO PRESENT FULL DATA FROM TRIAL AT A SCIENTIFIC CONGRESS IN 2020.MERCK & CO INC - PLANS TO PRESENT FULL DATA FROM TRIAL AT A SCIENTIFIC CONGRESS IN 2020..MERCK & CO INC - RELEBACTAM HAS RECEIVED U.S. FDA QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) DESIGNATION & FAST TRACK STATUS.

AstraZeneca, Merck Says Cancer Treatment Achieves Improvement In Progression-Free Survival

Sept 30 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT.ASTRAZENECA PLC - ANNOUNCED DETAILED POSITIVE RESULTS FROM PHASE III PAOLA-1 TRIAL.ASTRAZENECA - RESULTS SHOW LYNPARZA (OLAPARIB) DEMONSTRATED STATISTICALLY SIGNIFICANT IN PROGRESSION-FREE SURVIVAL IN WOMEN WITH NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER.ASTRAZENECA PLC - SAFETY AND TOLERABILITY PROFILE OF LYNPARZA AND BEVACIZUMAB WERE CONSISTENT WITH THOSE KNOWN FROM PREVIOUS TRIALS FOR EACH MEDICINE.

Merck’s PIFELTRO And DELSTRIGO Receive US FDA Approval For Use In Appropriate Adults Living With HIV-1 Who Are Virologically Suppressed

Sept 20 (Reuters) - Merck & Co Inc <MRK.N>::MERCK’S PIFELTRO™ (DORAVIRINE) AND DELSTRIGO™ (DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE) RECEIVE US FDA APPROVAL FOR USE IN APPROPRIATE ADULTS LIVING WITH HIV-1 WHO ARE VIROLOGICALLY SUPPRESSED.MERCK & CO INC - APPROVALS BASED ON FINDINGS FROM PHASE 3 DRIVE-SHIFT TRIAL EVALUATING A SWITCH TO DELSTRIGO.MERCK & CO INC - DELSTRIGO CONTAINS A BOXED WARNING REGARDING POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B VIRUS (HBV) INFECTION.

FDA Approves KEYTRUDA plus LENVIMA Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

Sept 17 (Reuters) - Merck & Co Inc <MRK.N>::FDA APPROVES KEYTRUDA® (PEMBROLIZUMAB) PLUS LENVIMA® (LENVATINIB) COMBINATION TREATMENT FOR PATIENTS WITH CERTAIN TYPES OF ENDOMETRIAL CARCINOMA.MERCK & CO INC - APPROVAL WAS BASED ON DATA FROM KEYNOTE-146/STUDY 111.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up